New combo therapy shows promise for Tough-to-Treat lymphoma

NCT ID NCT05364424

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a new drug, glofitamab, combined with standard chemotherapy (R-ICE) in 43 people with diffuse large B-cell lymphoma that returned or didn't respond to first treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the combination could shrink tumors and how safe it was.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

Chao Family Comprehensive Cancer Center UCI

Orange, California, 92868, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Cancer Institute at Memorial West

Pembroke Pines, Florida, 33028, United States
New York University Langone Medical Center

New York, New York, 10016, United States
The University of Chicago

Chicago, Illinois, 60637, United States
Tulane Medical Center

New Orleans, Louisiana, 70112, United States
UMASS Memorial Medical Center

Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.